In pharma, fair market value (FMV) is the most a company should pay a healthcare professional (HCP) for a bona fide service, such as speaking at a program, consulting, or sitting on an advisory board, based on the work and the HCP's expertise and never on the business the HCP could generate. Companies turn that principle into a rate card, which sets the fee for each engagement, and a cap, which limits what one HCP can be paid over a period. The fee for a single talk is usually called an honorarium.
Quick answer: FMV in pharma is the documented rate a company pays an HCP for a real service, set by the type of work, the hours, and the HCP's qualifications. The PhRMA Code says compensation for consultants and speakers should be reasonable, based on fair market value, and should not take into account the volume or value of past or potential business. The rate, the cap on total payments, and any exception to that cap should all be on the record before the payment is made.
Paying an HCP who prescribes or orders a company's products is legal when the payment is for a real service at a reasonable price. When the payment is more than the work is worth, it can look like a reward for prescribing, which is what the federal Anti-Kickback Statute prohibits. FMV is how a company shows the difference.
The government has been specific about this. In its November 2020 Special Fraud Alert on speaker programs, the HHS Office of Inspector General listed paying speakers more than fair market value, or paying in a way that reflects past or expected business, among the characteristics that suggest a program is suspect. The PhRMA Code on Interactions with Health Care Professionals, revised effective January 2022, uses the same standard for consultants, speakers, and speaker training, and says a company should engage only as many advisors as it reasonably needs for an identified purpose. How speaker programs are designed against the OIG alert is covered in pharma speaker programs.
Most companies set FMV with a written methodology, often built with an outside valuation firm and refreshed on a schedule. The methodology usually starts with an hourly rate and multiplies it by the time the service takes. The hourly rate varies by the HCP's specialty and by tier, which reflects experience such as academic appointments, publications, trial leadership, or guideline committee work. The hours depend on the service: a one-hour dinner talk, a full-day advisory board, or a consulting project each has its own allowance for preparation and delivery. Travel is reimbursed separately at reasonable cost.
The tier has to be assigned for documented reasons that have nothing to do with prescribing. A rate card that puts a high-volume prescriber in a higher tier without a matching change in credentials defeats the purpose of having one.
The rate covers one engagement. The cap covers the HCP's total payments, usually over a calendar year and across every brand and function in the company. Caps exist because a long run of individually reasonable engagements can still add up to an amount that looks like an inducement, and because the same HCP is often booked by several teams who cannot see each other's spend. How teams keep track of that running total is covered in speaker bureau FMV monitoring.
Sometimes there is a good reason to go past the cap. The HCP may be one of very few experts in a rare disease, or a launch may need the same advisor across several meetings. That is an exception, and it should be a decision someone makes and writes down before the payment, with who approved it and why. If the overage is first noticed in an audit after the payment, there is no decision to point to.
Together, these make the record a compliance team will want to see: the tier and the reason for it, the contract, the service actually delivered, the hours, the payment, the running total against the cap, and any exception. Payments to physicians and teaching hospitals are also reported publicly through the federal Open Payments program, so the same figures will be visible outside the company.
TikaSpeaker Bureau keeps the speaker, the contract, and the fair-market-value cap on one record. The cap warns at 80 percent and blocks the payment at 100 percent. An exception is a recorded decision.
Fair market value in pharma is the most a company should pay a healthcare professional for a bona fide service, such as speaking, consulting, or advising, based on the work and the HCP's qualifications. It must not reflect the volume or value of business the HCP has generated or could generate for the company.
Most use a written methodology that sets an hourly rate by specialty and tier, then multiplies it by the hours the service takes. Tiers reflect documented credentials such as academic roles, publications, and trial leadership. Many companies build and refresh the methodology with an outside valuation firm.
An FMV cap limits the total a company pays one HCP over a period, usually a calendar year, across all brands and functions. It stops a series of individually reasonable payments from adding up to an amount that could look like an inducement.
Yes. The PhRMA Code applies the fair market value standard to consultants, speakers, speaker training, and advisory boards. For advisory boards it also says the number of HCPs should be no more than is reasonably necessary for an identified purpose.
If your team checks the cap after the payment instead of before it, we can walk through how the speaker, the contract, and the cap look on one record.
Book a 20-minute walkthrough →